Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Pharmather Holdings Ltd C.PHRM

Alternate Symbol(s):  PHRRF

psychedelics
PharmaTher Holdings Ltd. is a Canada-based specialty pharmaceutical company. The Company develops and commercializes specialty pharmaceuticals exhibiting growing adoption and permitting delivery methods to enhance patient outcomes. Its lead product is KETARX (racemic ketamine) to fill the global unmet medical needs for anesthesia, sedation, pain, mental health, and neurological indications. The Company is also commercializing PharmaPatch (microneedle patch) with its partners to deliver psychedelics and drugs to treat infectious diseases.


CSE:PHRM - Post by User

Pharmather Holdings Ltd
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(433)
•••
Post by AwareInvestoron Jun 15, 2021 8:16am
142 Views
Post# 33387061

PharmaTher Applies For Pre-IND Meeting With US FDA For Ketab

PharmaTher Applies For Pre-IND Meeting With US FDA For Ketab
PharmaTher Holdings this morning announced that it continues to push forward with the development of Ketabet. The company has now formally applied for a pre-investigation new drug meeting with the US FDA for the development of the product.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities